Cover Image
市場調查報告書

Temozolomide的中國市場

Investigation Report on China Temozolomide Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 337523
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Temozolomide的中國市場 Investigation Report on China Temozolomide Market, 2010-2019
出版日期: 2015年08月18日 內容資訊: 英文 30 Pages
簡介

Temozolomide是Schering-Plough開發的動物膠腫 (神經膠質瘤) 的治療藥,1999年受FDA (美國食品藥物管理局) ,2000年受中國當局被認證。中國國內的Temozolomide的銷售額,2006年達到600萬人民幣,2014年達3億人民幣以上,以及2008∼2014年的年複合成長率(CAGR) 估計為約67%。

本報告提供中國的Temozolomide的市場相關分析、Temozolomide的特徵和認證情形、市場整體規模、各企業、各劑型的市場佔有率、價格趨勢、主要製造商簡介、今後的市場成長預測等調查評估。

第1章 Temozolomide的相關概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國的Temozolomide市場簡介

  • 中國國內的Temozolomide的專利申請、核準情況
  • 主要製造商
  • 市場規模

第3章 中國國內的Temozolomide銷售額分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 Temozolomide的主要廠商的市場佔有率 (過去5年份)

  • 市場佔有率 (以金額為準)
  • 市場佔有率 (以數量為準)

第5章 中國國內的Temozolomide的劑型 (過去5年份)

  • 各劑型的市場佔有率 (以金額為準)
  • 各劑型的市場佔有率 (以數量為準)

第6章 中國醫院的Temozolomide的參照價格

  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd
  • Orion (芬蘭)
  • Shanghai Schering-Plough Pharmaceutical Co., Ltd.
  • Beijing SL Pharmaceutical Co., Ltd

第7章 中國國內的Temozolomide的主要製造商 (過去5年份)

  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd
  • Orion (芬蘭)
  • Shanghai Schering-Plough Pharmaceutical Co., Ltd.
  • Beijing SL Pharmaceutical Co., Ltd

第8章 中國國內的Temozolomide市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境的預測

圖表一覽

目錄
Product Code: 1508306

Among all anti-tumor drugs, alkylating agent boasts of the longest history of application. Since nitrogen mustard was used to treat malignant lymphoma in 1942, alkylating agent has become the first-line anti-tumor drug due to its cheap price. The major varieties of alkylating agent are temozolomide and oxaliplatin. First developed by Schering-Plough, temozolomide was approved by FDA to treat glioma in 1999 and entered China since 2000.

Having efficacy in glioma, leukemia, melanoma, lymphoma and solid tumor, temozolomide can easily penetrate through blood-brain barrier and stay stable in acid environment with a broad antitumor spectrum and low toxicity. And it can be taken orally in patients who have drug resistance to nitrosoureas.

According to relevant statistics, about 60% of primary brain tumors are malignant ones. The incidence of malignant brain tumor in China is 80-100/1 million and the annual number of new cases is over 200,000. Temozolomide has reported a remarkable growth in global sales since its debut.

According to CRI's market survey, the sales value of temozolomide in sample hospitals rose from about CNY 6 million in 2006 to over CNY 300 million in 2014 with CAGR during the period of 2008-2014 reaching up to 67%. In 2014, the generic drug of temozolomide made by Tasly was approved to enter the market. Currently, temozolomide products available in the Chinese market come from the following four companies: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd, Orion (Finland), Schering-Plough and Beijing SL Pharmaceutical Co., Ltd, among which the former three dominate the market and Orion (Finland) had the largest market share of about 50.5% for sales value in 2014.

Readers can get at least the following information through this report:

  • market size of temozolomide in China
  • competitive landscape of temozolomide market in China
  • price of temozolomide made by different enterprises in China
  • market outlook of temozolomide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-tumor agents
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Temozolomide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Temozolomide in China

  • 2.1. Patent and Approval Information of Temozolomide in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Temozolomide Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Temozolomide Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Temozolomide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Temozolomide in Chinese Hospitals in 2014

  • 6.1. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd
  • 6.2. Orion (Finland)
  • 6.3. Shanghai Schering-Plough Pharmaceutical Co., Ltd.
  • 6.4. Beijing SL Pharmaceutical Co., Ltd

7. Major Manufacturers of Temozolomide in Chinese Market, 2010-2014

  • 7.1. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd
  • 7.2. Orion (Finland)
  • 7.3. Shanghai Schering-Plough Pharmaceutical Co., Ltd.
  • 7.4. Beijing SL Pharmaceutical Co., Ltd

8. Market Outlook of Temozolomide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Temozolomide in China
  • Chart Registration Information of Temozolomide in China
  • Chart Temozolomide Sales in China
  • Chart Sales Value of Temozolomide in China, 2010-2014
  • Chart Sales Value of Temozolomide in Some Regions in China, 2010-2014
  • Chart Sales Volume of Temozolomide in China, 2010-2014
  • Chart Sales Volume of Temozolomide in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Temozolomide Made by Orion (Finland) in China, 2010-2014
  • Chart Sales Value and Market Share of Temozolomide Made by Jiangsu Tasly Diyi in China, 2010-2014
  • Chart Sales Value and Market Share of Temozolomide Made by Schering-Plough in China, 2010-2014
  • Chart Sales Value and Market Share of Temozolomide Capsule in China, 2010-2014
  • Chart Price of Temozolomide Made by Jiangsu Tasly Diyi in Some Chinese Cities in 2014
  • Chart Price of Temozolomide Made by Orion (Finland) in Some Chinese Cities in 2014
  • Chart Price of Temozolomide Made by Schering-Plough in Some Chinese Cities in 2014
Back to Top